FDA clears first OTC glucose monitor for children

• Stelo uses a wearable sensor and smartphone app to display glucose readings and trends every 15 minutes, with each sensor lasting up to 15 days (potentially shorter in children)
• The device is approved only for patients who do not use insulin and is not designed to alert users about dangerously low blood sugar levels
• Children must use the device under adult supervision, and users should consult healthcare providers before changing medications based on its readings

FDA Clears First OTC Glucose Monitor for Pediatric Use

Key Development:

The U.S. Food and Drug Administration announced on June 12 the expansion of Dexcom's Stelo Glucose Biosensor System for pediatric use, marking the first over-the-counter continuous glucose monitor cleared for children with diabetes.

Product Specifications:

• Approved for patients aged two years and older who do not use insulin
• Previously cleared for adults 18+ in March 2024
• Features a wearable sensor paired with smartphone app providing glucose readings every 15 minutes
• Each sensor lasts up to 15 days (potentially shorter wear time in children)

Functionality:

The device helps children and caregivers track how meals, exercise, and lifestyle changes impact glucose levels. The system displays real-time readings and trends through continuous monitoring.

Important Limitations:

• Requires adult supervision for pediatric users
• Not designed for individuals with problematic low blood sugar
• Does not alert users to dangerously low glucose levels
• Users must consult healthcare providers before making medication adjustments based on readings

Market Implications:

This regulatory expansion represents a significant milestone in diabetes management technology, opening a new pediatric market segment for Dexcom. The OTC designation eliminates prescription requirements, potentially increasing accessibility and market penetration for continuous glucose monitoring in the non-insulin dependent pediatric population. This development positions Dexcom as the first mover in the pediatric OTC glucose monitoring space, potentially strengthening its competitive position in the broader diabetes care market.

Company: Dexcom (primary beneficiary)

Sector: Medical devices, diabetes care technology